Day: May 6, 2026

SYNGENE – Syngene International – Q4 FY26 Earnings Call – 30-Apr-26

SYNGENE’s topline resilience hinges on CDMO ramp-up and Librela dissipation, while margins remain range-bound (mid-20s) until facility utilization inflects; cash flow strength provides downside protection.

1–2 minutes

Also see: SYNGENE – Syngene International – Q4 FY26 Financial Results – 29-Apr-26

3-Scenario Framework

📊 Base Case (50% Probability)

Librela headwinds fully absorbed by FY27 end, with H2 FY27 revenue inflection driven by new CDMO contracts and stabilized research services. EBITDA margins hover in mid-20s as Bayview/Unit 3 costs offset utilization gains. Free cash flow remains robust (~INR500 crore annually), supporting capex and potential shareholder returns.

Continue reading “SYNGENE – Syngene International – Q4 FY26 Earnings Call – 30-Apr-26”